University of Groningen Cholesterol-Lowering Drugs and Incident Open-Angle Glaucoma

Background: Open-angle glaucoma (OAG) is a progressive neurodegenerative disease that may lead to blindness. An elevated intraocular pressure (IOP) is its major risk factor. OAG treatment is currently exclusively directed towards the lowering of the IOP. IOP lowering does not prevent disease progression in all patients and thus other treatment modalities are needed. Earlier studies reported cholesterol-lowering drugs to have neuroprotective properties. The aim of this study was to determine the associations between the use of cholesterol-lowering drugs and incident OAG. Methodology/Principal Findings: Participants in a prospective population-based cohort study underwent ophthalmic examinations, including IOP measurements and perimetry, at baseline and follow-up. The use of statins and non-statin cholesterol-lowering drugs was monitored continuously during the study. Associations between the use of cholesterollowering drugs and incident OAG were analyzed with Cox regression; associations between cholesterol-lowering drugs and IOP at follow-up were analyzed with multiple linear regression. During a mean follow-up of 9.8 years, 108 of 3939 eligible participants (2.7%) developed OAG. The hazard ratio for statin use was 0.54 (95% confidence interval 0.31–0.96; P = 0.034) and for non-statin cholesterol-lowering drugs 2.07 (0.81–5.33; P = 0.13). The effect of statins was more pronounced with prolonged use (hazard ratio 0.89 [0.41–1.94; P = 0.77] for use two years or less; 0.46 [0.23–0.94; P = 0.033] for use more than two years; P-value for trend 0.10). The analyzes were adjusted for age and gender, baseline IOP and IOP-lowering treatment, the family history of glaucoma, and myopia. There was no effect of statins on the IOP. Conclusions/Significance: Long-term use of statins appears to be associated with a reduced risk of OAG. The observed effect was independent of the IOP. These findings are in line with the idea that statins have neuroprotective properties and may open a way to a new OAG treatment modality. Citation: Marcus MW, Müskens RPHM, Ramdas WD, Wolfs RCW, De Jong PTVM, et al. (2012) Cholesterol-Lowering Drugs and Incident Open-Angle Glaucoma: A Population-Based Cohort Study. PLoS ONE 7(1): e29724. doi:10.1371/journal.pone.0029724 Editor: Pablo Villoslada, Institute Biomedical Research August Pi Sunyer (IDIBAPS) Hospital Clinic of Barcelona, Spain Received May 11, 2011; Accepted December 3, 2011; Published January 4, 2012 Copyright: 2012 Marcus et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Funding: Stichting Lijf en Leven, Krimpen aan de Lek; MD Fonds, Utrecht; Rotterdamse Vereniging Blindenbelangen, Rotterdam; Stichting Oogfonds Nederland, Utrecht; Blindenpenning, Amsterdam; Blindenhulp, The Hague; Algemene Nederlandse Vereniging ter Voorkoming van Blindheid (ANVVB), Doorn; Landelijke Stichting voor Blinden en Slechtzienden, Utrecht; Swart van Essen, Rotterdam; Stichting Winckel-Sweep, Utrecht; Henkes Stichting, Rotterdam; Professor Mulder Stichting, Groningen; Stichting Nederlands Oogheelkundig Onderzoek, Rotterdam; Laméris Ootech BV, Nieuwegein; Medical Workshop, de Meern; Topcon Europe BV, Capelle aan de IJssel, all in the Netherlands and Heidelberg Engineering, Dossenheim, Germany. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Competing Interests: This study was partly funded by the following companies: Laméris Ootech BV, Medical Workshop, Topcon Europe BV and Heidelberg Engineering. The funding was unrestricted and did not, in any way, interfere with the conception and/or design and/or outcome and/or publication of the study. There are no patents, products in development or marketed products to declare. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials. * E-mail: b.stricker@erasmusmc.nl

[1]  C. Ekström,et al.  Risk factors for incident open‐angle glaucoma: a population‐based 20‐year follow‐up study , 2012, Acta ophthalmologica.

[2]  N. Jansonius,et al.  Myopia as a risk factor for open-angle glaucoma: a systematic review and meta-analysis. , 2011, Ophthalmology.

[3]  J. Burgos,et al.  Statins as neuroprotectants: a comparative in vitro study of lipophilicity, blood-brain-barrier penetration, lowering of brain cholesterol, and decrease of neuron cell death. , 2011, Journal of Alzheimer's disease : JAD.

[4]  D. Cook,et al.  Hypotensive medication, statins, and the risk of glaucoma. , 2010, Investigative ophthalmology & visual science.

[5]  U. Igbavboa,et al.  Statins and neuroprotection , 2010, Annals of the New York Academy of Sciences.

[6]  B. Stricker,et al.  Analysis of individual drug use as a time-varying determinant of exposure in prospective population-based cohort studies , 2010, European Journal of Epidemiology.

[7]  C. Tham,et al.  Simvastatin and disease stabilization in normal tension glaucoma: a cohort study. , 2010, Ophthalmology.

[8]  G. Chodick,et al.  Persistence with statins and incident cataract: a population-based historical cohort study. , 2010, Annals of epidemiology.

[9]  A. Hofman,et al.  Incidence of glaucomatous visual field loss: a ten-year follow-up from the Rotterdam Study. , 2010, Ophthalmology.

[10]  P. Passmore,et al.  Statins for the treatment of dementia , 2010, Alzheimer's & Dementia.

[11]  T. Einarson,et al.  Effect of selected antihypertensives, antidiabetics, statins and diuretics on adjunctive medical treatment of glaucoma: A population based study* , 2009, Current medical research and opinion.

[12]  R. Mott,et al.  Systemic administration of HMG-CoA reductase inhibitor protects the blood-retinal barrier and ameliorates retinal inflammation in type 2 diabetes. , 2009, Experimental eye research.

[13]  A. Dolga,et al.  Statins: Mechanisms of neuroprotection , 2009, Progress in Neurobiology.

[14]  D. Alexopoulos,et al.  Pseudoexfoliation syndrome prevalence in Greek patients with cataract and its association to glaucoma and coronary artery disease , 2009, Eye.

[15]  Monique M. B. Breteler,et al.  The Rotterdam Study: 2016 objectives and design update , 2015, European Journal of Epidemiology.

[16]  P. Mitchell,et al.  Statin use and the long-term risk of incident cataract: the Blue Mountains Eye Study. , 2007, American journal of ophthalmology.

[17]  W. Howard Statin Use and Incident Nuclear Cataract , 2007 .

[18]  M. Çıtırık,et al.  A possible link between the pseudoexfoliation syndrome and coronary artery disease , 2007, Eye.

[19]  R. Stamper,et al.  Effect of Statin Drugs and Aspirin on Progression in Glaucoma Suspects , 2006 .

[20]  L. Kuo,et al.  Effect of systemic administration of simvastatin on retinal circulation. , 2006, Archives of ophthalmology.

[21]  S. Czuczwar,et al.  Neuroprotective properties of statins. , 2005, Pharmacological reports : PR.

[22]  Michael Schachter,et al.  Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update , 2005, Fundamental & clinical pharmacology.

[23]  A. Hofman,et al.  Causes of incident visual field loss in a general elderly population: the Rotterdam study. , 2005, Archives of ophthalmology.

[24]  John H Fuller,et al.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.

[25]  C. Owsley,et al.  Statins and other cholesterol-lowering medications and the presence of glaucoma. , 2004, Archives of ophthalmology.

[26]  T. Walley,et al.  Variations and increase in use of statins across Europe: data from administrative databases , 2004, BMJ : British Medical Journal.

[27]  G. Mancia,et al.  European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force Of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). , 2004, Archives des maladies du coeur et des vaisseaux.

[28]  Ida Dielemans,et al.  Reliability of intraocular pressure measurement with the Goldmann applanation tonometer in epidemiological studies , 1994, Graefe's Archive for Clinical and Experimental Ophthalmology.

[29]  C. Curcio,et al.  Complex mutations of USH2A gene denote ARRP , 2003, The British journal of ophthalmology.

[30]  Sarah Parish,et al.  MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial , 2003, The Lancet.

[31]  A. Hofman,et al.  Cholesterol-lowering drugs and risk of age-related maculopathy: prospective cohort study and cumulative exposure measurement☆ , 2003 .

[32]  Chris A. Johnson,et al.  The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. , 2002, Archives of ophthalmology.

[33]  R. Pandey,et al.  Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. , 2002, Diabetes research and clinical practice.

[34]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.

[35]  A. Hofman,et al.  Changing views on open-angle glaucoma: definitions and prevalences--The Rotterdam Study. , 2000, Investigative ophthalmology & visual science.

[36]  F. Bernini,et al.  New insights into the pharmacodynamic and pharmacokinetic properties of statins. , 1999, Pharmacology & therapeutics.

[37]  N. Delanty,et al.  Neuroprotective properties of statins in cerebral ischemia and stroke. , 1999, Stroke.

[38]  J. J. Wang,et al.  Association of pseudoexfoliation syndrome with increased vascular risk. , 1997, American journal of ophthalmology.

[39]  A. Endo,et al.  The discovery and development of HMG-CoA reductase inhibitors. , 1992, Journal of lipid research.

[40]  S. Grundy HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. , 1988, The New England journal of medicine.